Waystar stock reiterated at Buy by TD Cowen on valuation

Waystar reported Q1 fiscal 2026 revenue of $314.0 million, slightly above the $313.9 million consensus, with EPS of $0.22 and adjusted EBITDA about 5% above expectations. TD Cowen reiterated a Buy rating and $42 price target, saying the recent 18.5% weekly selloff looks overdone and that weather-related weakness and exchange volume headwinds are temporary. UBS and Goldman Sachs also kept Buy ratings while trimming targets to $37 and $33, respectively.

Analysis

WAY looks like a classic post-print dislocation where the market is punishing headline optics rather than cash generation. The key second-order issue is that the revenue mix noise is doing more damage to sentiment than to economics; that usually creates a cleaner re-rating setup than a simple beat/miss because the selloff can unwind once investors re-anchor on EBITDA and cash conversion. The fact that multiple brokers are trimming targets but keeping Buy ratings suggests the street is de-risking estimate precision, not the underlying thesis.

The more interesting read-through is to other high-multiple healthcare software names with recurring revenue models: when the market starts to question “quality of growth,” it tends to compress EV/revenue multiples broadly, even if the issue is isolated. That creates a window to own the best operators and fade the weakest balance-sheet stories in adjacent vertical SaaS, since any temporary volume or accounting drag is being treated as secular impairment. If management can hold full-year guidance for another quarter, the stock should mean-revert quickly because the current price already implies a material probability of a second downgrade that is not yet evident in the numbers.

The contrarian angle is that the selloff may still be too shallow if the market is underestimating how long it takes for confidence to recover after a guidance-maintenance quarter. In software names, “we kept the guide” often reads as “no positive revision catalyst for 1-2 quarters,” which can cap multiple expansion even if fundamentals remain intact. So the trade is not just about being right on earnings quality; it is about whether buyers are willing to pay up before the next catalyst, and that answer is usually only yes after a few weeks of stabilization.

Key Decisions for Investors

• Buy WAY on weakness over the next 3-10 trading days if it holds above the recent low; target a 10-15% rebound toward prior support, with a tight stop 5-7% below the current base.
• For more convex exposure, buy WAY 2-3 month call spreads financed with a lower strike put sale only if volatility remains elevated; aim for 2:1 or better upside/downside.
• Pair trade: long WAY / short a lower-quality vertical SaaS or healthcare IT peer with weaker margins and slower organic growth over 1-2 months to isolate the re-rating from broader sector noise.
• If WAY loses the post-earnings base and closes below the 52-week low, exit the long and wait for the next catalyst cycle; this would signal the market is pricing in a guide cut rather than transitory noise.
• Use UBS/GS as a sentiment gauge: if target cuts stop and estimates stabilize, add to WAY; if additional reductions follow within 2-4 weeks, reduce size because the de-rating could extend another 10-15%.